Rehmann Capital Advisory Group Acquires 76 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rehmann Capital Advisory Group increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 601 shares of the biopharmaceutical company’s stock after acquiring an additional 76 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Regeneron Pharmaceuticals were worth $578,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 23.2% during the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after buying an additional 5,495 shares during the period. Sierra Summit Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $1,011,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $749,000. Public Employees Retirement Association of Colorado grew its stake in Regeneron Pharmaceuticals by 16.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after purchasing an additional 2,220 shares during the period. Finally, Exchange Traded Concepts LLC lifted its position in Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after buying an additional 1,221 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. JPMorgan Chase & Co. raised their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Monday, June 17th. Royal Bank of Canada reissued an “outperform” rating and issued a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,035.73.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 63,208 shares of company stock valued at $62,514,142. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $8.88 on Thursday, reaching $1,080.00. The stock had a trading volume of 18,817 shares, compared to its average volume of 469,771. The stock has a market cap of $119.01 billion, a P/E ratio of 31.64, a price-to-earnings-growth ratio of 2.17 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals, Inc. has a 1 year low of $714.15 and a 1 year high of $1,081.17. The company has a 50 day simple moving average of $1,008.01 and a 200 day simple moving average of $961.64.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.